Tag: Novo Nordisk

Market News

Premarket Movers: Starbucks, Peloton, and More

Starbucks jumps 4% as its turnaround shines, while Peloton surges 7%. Novo Nordisk slips—what’s driving these moves? Click to uncover...

30/07/2025

2 views

Read More

Market News

Why Novo Nordisk Shares Plunged: Obesity Drug Market Woes

Novo Nordisk’s shares tanked after a slashed forecast. Compounded GLP-1 drugs are eating into Wegovy’s market. Is this a dip...

29/07/2025

2 views

Read More

Market News

Novo Nordisk Stock Dips: What’s Behind the Drop?

Novo Nordisk shares tanked 15% after slashing 2025 guidance. What's causing the dip in Wegovy and Ozempic sales? Dive into...

29/07/2025

2 views

Read More

Market News

Why Weight Loss Drugs Spark Market Buzz

Eli Lilly’s obesity drug Zepbound faces a CVS-Wegovy deal. Will it shake their market lead? Dive into the drama...

07/05/2025

0 views

Read More

Market News

Novo’s Fight Against Copycat Obesity Drugs

Novo Nordisk slashes its 2025 forecast but surges 6.5% as it vows to crush copycat obesity drugs. Will Wegovy reclaim...

07/05/2025

0 views

Read More

Market News

Hims & Hers Soars With Novo Nordisk Wegovy Deal

Hims & Hers stock skyrockets 27% with Novo Nordisk's Wegovy deal. What’s driving this telehealth surge, and is it time...

29/04/2025

0 views

Read More

Global Companies

Weight Loss Drugs: Legal Battles and Safety Risks

Novo Nordisk's legal victory limits compounded Wegovy and Ozempic. What does this mean for patients seeking affordable options? Click to...

25/04/2025

0 views

Read More